NCT07081126 - Daratumumab for Late Antibody-Mediated Rejection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Kidney TansplantAcute Rejection (AR) of Transplanted Kidney

Interventions

DRUG

Daratumumab (Subcutaneously)

Kidney transplant recipients with late ABMR and de novo DSA treated with daratumumab (1800mg subcutaneous, weekly x 4, then monthly x 6).

OTHER

control group

Kidney transplant recipients with late ABMR and de novo DSA treated with standard therapies (IVIG, plasmapheresis, rituximab, etc.) prior to the start of the daratumumab study.

Trial Locations (1)

03601

RECRUITING

University hospital Martin, Martin

All Listed Sponsors

lead

University Hospital, Martin

OTHER